ABT-751 in Treating Young Patients With Refractory Solid Tumors

Completed · Phase 1

Conditions studied: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific

In brief

RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects of ABT-751 in treating young patients with refractory solid tumors.

Key facts

Study ID

NCT00036959

Run by

National Institutes of Health Clinical Center (CC)

People needed

90

Starts

2002-03-01

Expected to finish

2010-02-01

Last updated by the study team

2012-03-15

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Children's Memorial Hospital - Chicago — Chicago, Illinois, United States
• Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office — Bethesda, Maryland, United States
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.